IDEXX Laboratories, Inc. (IDXX) Holdings Decreased by Navellier & Associates Inc

Navellier & Associates Inc cut its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 15.4% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 61,665 shares of the company’s stock after selling 11,246 shares during the period. IDEXX Laboratories makes up 1.5% of Navellier & Associates Inc’s holdings, making the stock its 12th biggest holding. Navellier & Associates Inc owned approximately 0.07% of IDEXX Laboratories worth $9,954,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds also recently made changes to their positions in the business. USA Financial Portformulas Corp acquired a new stake in shares of IDEXX Laboratories during the second quarter valued at about $6,355,000. HWG Holdings LP increased its position in shares of IDEXX Laboratories by 90.3% during the second quarter. HWG Holdings LP now owns 11,131 shares of the company’s stock valued at $1,797,000 after acquiring an additional 5,281 shares during the last quarter. Toronto Dominion Bank increased its position in shares of IDEXX Laboratories by 25.6% during the second quarter. Toronto Dominion Bank now owns 29,853 shares of the company’s stock valued at $4,818,000 after acquiring an additional 6,085 shares during the last quarter. Advisory Services Network LLC increased its position in shares of IDEXX Laboratories by 26.3% during the second quarter. Advisory Services Network LLC now owns 3,349 shares of the company’s stock valued at $541,000 after acquiring an additional 697 shares during the last quarter. Finally, Dynamic Technology Lab Private Ltd acquired a new stake in shares of IDEXX Laboratories during the second quarter valued at about $376,000. Institutional investors and hedge funds own 87.64% of the company’s stock.

Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) traded down 0.18% on Tuesday, hitting $158.00. 91,800 shares of the company were exchanged. The firm has a market cap of $13.79 billion, a P/E ratio of 54.35 and a beta of 0.48. The company has a 50-day moving average price of $156.04 and a 200 day moving average price of $159.86. IDEXX Laboratories, Inc. has a 52-week low of $102.45 and a 52-week high of $173.01.

IDEXX Laboratories (NASDAQ:IDXX) last posted its earnings results on Tuesday, August 1st. The company reported $0.95 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.85 by $0.10. The firm had revenue of $508.90 million during the quarter, compared to the consensus estimate of $502.44 million. IDEXX Laboratories had a net margin of 14.13% and a negative return on equity of 473.46%. The company’s revenue was up 9.1% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.74 EPS. Analysts predict that IDEXX Laboratories, Inc. will post $3.18 EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: This piece of content was first reported by Community Financial News and is the property of of Community Financial News. If you are accessing this piece of content on another publication, it was illegally copied and republished in violation of United States and international copyright legislation. The legal version of this piece of content can be read at https://www.com-unik.info/2017/10/10/idexx-laboratories-inc-idxx-holdings-decreased-by-navellier-associates-inc.html.

IDXX has been the subject of a number of recent analyst reports. BidaskClub cut shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Monday, July 31st. Canaccord Genuity reiterated a “buy” rating and set a $180.00 price target on shares of IDEXX Laboratories in a research report on Friday. Stifel Nicolaus reiterated a “buy” rating and set a $185.00 price target on shares of IDEXX Laboratories in a research report on Friday, July 14th. Bank of America Corporation upgraded shares of IDEXX Laboratories from a “neutral” rating to a “buy” rating and set a $175.00 price target for the company in a research report on Wednesday, August 23rd. Finally, CL King upgraded shares of IDEXX Laboratories from a “neutral” rating to a “buy” rating and set a $200.00 price target for the company in a research report on Friday, July 28th. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the company. IDEXX Laboratories has a consensus rating of “Hold” and a consensus target price of $174.00.

In related news, Director Rebecca M. Henderson sold 5,156 shares of the stock in a transaction that occurred on Wednesday, August 23rd. The shares were sold at an average price of $153.29, for a total transaction of $790,363.24. Following the completion of the sale, the director now owns 17,274 shares of the company’s stock, valued at approximately $2,647,931.46. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Chairman Jonathan W. Ayers sold 13,000 shares of the stock in a transaction that occurred on Monday, August 28th. The stock was sold at an average price of $150.79, for a total transaction of $1,960,270.00. Following the sale, the chairman now directly owns 1,044,034 shares of the company’s stock, valued at approximately $157,429,886.86. The disclosure for this sale can be found here. In the last three months, insiders have sold 151,734 shares of company stock valued at $23,436,626. Corporate insiders own 2.77% of the company’s stock.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. The Company also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market.

Institutional Ownership by Quarter for IDEXX Laboratories (NASDAQ:IDXX)

What are top analysts saying about IDEXX Laboratories Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for IDEXX Laboratories Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit